SYO 1909
Alternative Names: SYO-1909Latest Information Update: 29 Sep 2023
Price :
$50 *
At a glance
- Originator Samyang Biopharmaceuticals Corporation
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Clinical Phase Unknown Cancer
Most Recent Events
- 22 Aug 2023 Clinical trials in Cancer (PO), before August 2023 (Samyang Biopharmaceuticals Corporation pipeline, August 2023)